市场分析报告 -

Online Database of Chemicals from Around the World

产品搜索 | 产品提交 | 产品推广

网站主页 >> 化工产品目录 >> >> 市场分析报告

市场分析报告

Evobrutinib (M2951) - Emerging Drug Insight and Market Forecast – 2030
... including B lymphocytes and macrophages. Evobrutinib is designed to inhibit primary B ... and access to available databases. Evobrutinib (M2951) Analytical Perspective by ... DelveInsight In-depth Evobrutinib (M2951) Market Assessment This ...

2020 Encephalomyelitis Drug Pipeline Report- Current Status, Phase, Mechanism, Route of Administration, and Companies, of Pre-Clinical And Clinical Drugs
... neurodegenerative disorders, CT38, MCC950, KPAX002, Evobrutinib, F8-IL4, RBM-001

Relapsing-remitting multiple sclerosis - Pipeline Insight, 2021
... and is currently in phase 3 stage of development. Evobrutinib: Merck Evobrutinib (M2951) is in clinical development to investigate ... be therapeutically useful in certain autoimmune diseases. Evobrutinib is currently under clinical investigation and ...

Bruton’s Tyrosine Kinase (BTK) Inhibitor - Pipeline Insight, 2022
... company was acquired by Sanofi. Evobrutinib: Merck Evobrutinib (M-2951) is an orally administered ... the protein is naturally degraded. Evobrutinib is designed to inhibit primary B ... without directly affecting T cells. Evobrutinib is currently undergoing Phase ...

Rheumatoid Arthritis: KOL Insight [2018]
... ) Bruton kinase inhibitors (e.g. Merck Serono’s evobrutinib) KOLs interviewed KOLs from North ...

Central Nervous System Therapeutics Market Size, Share & Trends Analysis Report By Disease, By Drug Class (Anticonvulsants, CNS Stimulants), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030
... drug candidates such as aducanumab, brexpiprozole, evobrutinib, solanezumab are some of the potential ...